2024/10/18 22:00:02 | |
---|---|
Price | |
346.37 USD | |
Difference | 0.69% (2.39) |
ISIN | US0905722072 |
Symbol | BIO |
Exchange | NYSE |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 7,291 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 338.51 USD (100) |
Ask (Ask size) | 353.41 USD (100) |
Open | 343.95 USD |
High | 347.13 USD |
Low | 338.84 USD |
Close (prev. day) | 343.98 USD |
VWAP | 345.30209 USD |
Volume (pcs) | 190,992 |
Trading volume | 65,857,487.95 |
Number of trades | 7,405 |
Last size | - |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/10/08 | Global Strategy 4Q 2024 | ||
2024/09/27 | Global Equity Ratings | ||
2024/09/11 | Global Equity Ratings | ||
2024/09/05 | Global Equity Ratings | ||
2024/08/12 | Global Equity Ratings |
2024/10/18 22:00:02 | |
---|---|
Price | |
346.37 USD | |
Difference | 0.69% (2.39) |
ISIN | US0905722072 |
Symbol | BIO |
Exchange | NYSE |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 7,291 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 338.51 USD (100) |
Ask (Ask size) | 353.41 USD (100) |
Open | 343.95 USD |
High | 347.13 USD |
Low | 338.84 USD |
Close (prev. day) | 343.98 USD |
VWAP | 345.30209 USD |
Volume (pcs) | 190,992 |
Trading volume | 65,857,487.95 |
Number of trades | 7,405 |
Last size | - |
6m | 1Y | 3Y | |
Perf (%) | +23.25% | +10.31% | -52.37% |
Perf (abs.) | +65.35 | +32.37 | -380.80 |
Beta | 0.62 | 0.84 | 0.96 |
Volatility | 31.07 | 31.87 | 36.36 |
Ø price 5 days | Ø volume 5 days (pcs.) | 340.67 USD (184,492) |
Ø price 30 days | Ø volume 30 days (pcs.) | 333.86 USD (394,697) |
Ø price 100 days | Ø volume 100 days (pcs.) | 313.36 USD (295,876) |
Ø price 250 days | Ø volume 250 days (pcs.) | 312.14 USD (263,176) |
YTD High | date | 364.24 USD (2024/02/16) |
YTD Low | date | 262.12 USD (2024/07/02) |
52 Weeks High | date | 364.24 USD (2024/02/16) |
52 Weeks Low | date | 261.59 USD (2023/10/30) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/10/18 | 22:26 | 318.70 EUR | 0.01 | 1 |
Stuttgart | 2024/10/18 | 21:31 | 314.80 EUR | 0.00 | 4 |
NYSE | 2024/10/18 | 22:00 | 346.37 USD | 65.86 | 7,405 |
Munich | 2024/10/18 | 08:01 | 315.80 EUR | 0.00 | 1 |
Frankfurt | 2024/10/18 | 08:20 | 315.80 EUR | 0.00 | 2 |
Duesseldorf | 2024/10/18 | 19:31 | 316.60 EUR | 0.00 | 7 |
Berlin | 2024/10/18 | 08:08 | 315.70 EUR | 0.00 | 2 |
BIO-RAD LABORATORIES INC. |
- - |
1000 Alfred Nobel Drive - 94547 Hercules |
Telefon: +1-510-724-7000 |
Fax: +1-510-741-5817 |
E-mail: ask_customer_care@bio-rad.com |
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA. |
Alice Schwartz | Member of Board of Directors |
Allison Schwartz | Member of Board of Directors |
Arnold Pinkston | Member of Board of Directors |
Gregory Hinckley | Member of Board of Directors |
Jeffrey Edwards | Member of Board of Directors |
Melinda Litherland | Member of Board of Directors |
Norman Schwartz | Chairman of Managing Board |
Ajit Ramalingam | Member of Executive Committee |
Andrew Last | Member of Executive Committee |
Annette Tumolo | Member of Executive Committee |
Dara Wright | Member of Executive Committee |
Ilan Daskal | Member of Executive Committee |
Mike Crowley | Member of Executive Committee |
Timothy Ernst | Member of Executive Committee |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer